

conservation of domain I in this study suggests that the intact form of domain I is required for efficient RNA replication. Genetic analysis in further long-term cell cultures will specifically clarify the critical domains required for the maintenance of RNA replication.

The unexpected phenomenon in this study was the time-dependent increase of the GC content of the HCV genome. After 1 year in culture, the GC content increased 0.14% (mean of five cell culture lines), corresponding to 15 nts per HCV genome, and during the next 1 year in culture, the GC content increased an additional 0.24% (mean of five cell culture lines), corresponding to 26 nts per HCV genome. Consequently, approximately 40 nts per HCV genome changed to a G or C residue during the 2 years in culture. The HCV genome may gradually change to an energetically stable form during RNA replication. The other possibility is that the increase in GC content may be due to an increase in G- and C-ending codons, except AGG and TTG codons, for efficient expression in human cells (codon optimization) [14]. However, our study revealed that the increase of G- and C-ending codons other than codons AGG and TTG was only 16–18% of the increase of GC content observed during the 2-year cultures of O-OE cells. To understand the mechanism underlying the increase of the GC content of genome-length HCV RNA during long-term RNA replication, further long-term cell cultures will be needed.

This study demonstrated that a single HCV genome could exhibit a quasispecies nature after 2 years in cell culture with RNA replication. Such quasispecies populations of HCV obtained by long-term cell culture may be useful not only for further analysis of the genetic variations and diversity of HCV but also for analysis of the sensitivity of reagents such as interferon against HCV.

Acknowledgments We thank T. Nakamura for his technical assistance. This work was supported by a grant-in-aid for the third-term comprehensive 10-year strategy for cancer control and by a grant-in-aid for research on hepatitis, both from the Ministry of Health, Labor, and Welfare of Japan.

References

1. Abe K, Ikeda M, Dansako H, Naka K, Kato N (2007) Cell culture-adaptive NS3 mutations required for the robust replication of genome-length hepatitis C virus RNA. *Virus Res* 125:88–97
2. Ariumi Y, Kuroki M, Abe K, Dansako H, Ikeda M, Wakita T, Kato N (2007) DDX3 DEAD-box RNA helicase is required for hepatitis C virus RNA replication. *J Virol* 81:13922–13926
3. Bartenschlager R (2005) The hepatitis C virus replicon system: from basic research to clinical application. *J Hepatol* 43:210–216
4. Bukh J, Miller RH, Purcell RH (1995) Genetic heterogeneity of hepatitis C virus: quasispecies and genotypes. *Semin Liver Dis* 15:41–63
5. Hijikata M, Kato N, Ootsuyama Y, Nakagawa M, Shimotohno K (1991) Gene mapping of the putative structural region of the hepatitis C virus genome by *in vitro* processing analysis. *Proc Natl Acad Sci USA* 88:5547–5551
6. Hijikata M, Mizushima H, Tanji Y, Komoda Y, Hirowatari Y, Akagi T, Kato N, Kimura K, Shimotohno K (1993) Proteolytic processing and membrane association of putative nonstructural proteins of hepatitis C virus. *Proc Natl Acad Sci USA* 90:10773–10777
7. Ikeda M, Abe K, Dansako H, Nakamura T, Naka K, Kato N (2005) Efficient replication of a full-length hepatitis C virus genome, strain O, in cell culture, and development of a luciferase reporter system. *Biochem Biophys Res Commun* 329:1350–1359
8. Kato N (2001) Molecular virology of hepatitis C virus. *Acta Med Okayama* 55:133–159
9. Kato N, Hijikata M, Ootsuyama Y, Nakagawa M, Ohkoshi S, Sugimura T, Shimotohno K (1990) Molecular cloning of the human hepatitis C virus genome from Japanese patients with non-A, non-B hepatitis. *Proc Natl Acad Sci USA* 87:9524–9528
10. Kato N, Sekiya H, Ootsuyama Y, Nakazawa T, Hijikata M, Ohkoshi S, Shimotohno K (1993) Humoral immune response to hypervariable region I of the putative envelope glycoprotein (gp70) of hepatitis C virus. *J Virol* 67:3923–3930
11. Kato N, Sugiyama K, Namba K, Dansako H, Nakamura T, Takami M, Naka K, Nozaki A, Shimotohno K (2003) Establishment of a hepatitis C virus subgenomic replicon derived from human hepatocytes infected *in vitro*. *Biochem Biophys Res Commun* 306:756–766
12. Kato N, Nakamura T, Dansako H, Namba K, Abe K, Nozaki A, Naka K, Ikeda M, Shimotohno K (2005) Genetic variation and dynamics of hepatitis C virus replicons in long-term cell culture. *J Gen Virol* 86:645–656
13. Kishine H, Sugiyama K, Hijikata M, Kato N, Takahashi H, Noshi T, Nio Y, Hosaka M, Miyanari Y, Shimotohno K (2002) Subgenomic replicon derived from a cell line infected with the hepatitis C virus. *Biochem Biophys Res Commun* 293:993–999
14. Kliman RM, Bernal CA (2005) Unusual usage of AGG and TTG codons in humans and their viruses. *Gene* 352:92–99
15. Lohmann V, Korner F, Koch J, Herian U, Theilmann L, Bartenschlager R (1999) Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. *Science* 285:110–113
16. Major ME, Mihalik K, Fernandez J, Seidman J, Kleiner D, Kolykhalov A, Rice CM, Feinstone SM (1999) Long-term follow-up of chimpanzees inoculated with the first infectious clone for hepatitis C virus. *J Virol* 73:3317–3325
17. Ogata N, Alter HJ, Miller RH, Purcell RH (1991) Nucleotide sequence and mutation rate of the H strain of hepatitis C virus. *Proc Natl Acad Sci USA* 88:3392–3396
18. Okamoto H, Kojima M, Okada S, Yoshizawa H, Iizuka H, Tanaka T, Muchmore EE, Peterson DA, Ito Y, Mishiro S (1992) Genetic drift of hepatitis C virus during an 8.2-year infection in a chimpanzee: variability and stability. *Virology* 190:894–899
19. Simmonds P (2004) Genetic diversity and evolution of hepatitis C virus—15 years on. *J Gen Virol* 85:3173–3188
20. Tanaka T, Kato N, Nakagawa M, Ootsuyama Y, Cho MJ, Nakazawa T, Hijikata M, Ishimura Y, Shimotohno K (1992) Molecular cloning of hepatitis C virus genome from a single Japanese carrier: sequence variation within the same individual and among infected individuals. *Virus Res* 23:39–53
21. Tellinghuisen TL, Marcotrigiano J, Gorbalenya AE, Rice CM (2004) The NS5A protein of hepatitis C virus is a zinc metalloprotein. *J Biol Chem* 279:48576–48587
22. Tellinghuisen TL, Marcotrigiano J, Rice CM (2005) Structure of the zinc-binding domain of an essential component of the hepatitis C virus replicase. *Nature* 435:374–379

23. Thomas DL (2000) Hepatitis C epidemiology. *Curr Top Microbiol Immunol* 242:25–41
24. Weiner A, Erickson AL, Kansopon J, Crawford K, Muchmore E, Hughes AL, Houghton M, Walker CM (1995) Persistent hepatitis C virus infection in a chimpanzee is associated with emergence of a cytotoxic T lymphocyte escape variant. *Proc Natl Acad Sci USA* 92:2755–2759



Oncostatin M synergistically inhibits HCV RNA replication in combination with interferon- α

Masanori Ikeda*, Kyoko Mori, Yasuo Ariumi, Hiromichi Dansako, Nobuyuki Kato

Department of Tumor Virology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Okayama 700-8558, Japan

ARTICLE INFO

Article history:

Received 23 February 2009

Revised 17 March 2009

Accepted 24 March 2009

Available online 28 March 2009

Edited by Hans-Dieter Klenk

Keywords:

Oncostatin M

Interferon

Hepatitis C virus

ABSTRACT

Oncostatin M (OSM), a member of the interleukin-6 family, possesses various functions, including hepatocyte differentiation and suppression of melanoma cell growth. Here, we report anti-hepatitis C virus (HCV) activity of OSM as a new function of this cytokine. OSM possessed marked anti-HCV activity (50% effective concentration: 0.71 ng/ml) in an HCV RNA replication cell culture system. The most striking finding is that OSM exhibited synergistic inhibitory activity on interferon (IFN)- α even at a low concentration with weak anti-HCV activity, such as 25 pg/ml. OSM is a candidate anti-HCV reagent and may improve the current IFN therapy for patients with chronic hepatitis C. © 2009 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.

1. Introduction

Currently the combination therapy of pegylated-interferon- α (PEG-IFN- α) with ribavirin (RBV) is available for patients with chronic hepatitis C (CH C). However, the sustained virological response (SVR) rate is still approximately 55% [1]. There is thus an urgent need for novel partners for IFN.

Oncostatin M (OSM) belongs to the interleukin (IL)-6 family, which also includes IL-6, IL-11, IL-27, ciliary neurotrophic factor, cardiotrophin-like cytokine, cardiotrophin-1, neuropoietin and leukemia-inhibitory factor (LIF) [2,3]. OSM was first reported as a cytokine produced from U-937 lymphoma cells, when it was found to inhibit the growth of melanoma cells [4]. The IL-6 family members share glycoprotein 130 (gp130) for signal transduction, and the OSM receptor consists of gp130 and its unique OSMR [5]. Recently it was reported that the IL-31 receptor also contains OSMR and forms a heterodimer with IL31RA [6]. OSMR and gp130 are highly expressed in liver, and OSM plays a significant role in the differentiation and regeneration of liver [7,8]. Therefore,

OSM was used as a reagent for the differentiation of hepatocytes in vitro.

Here, we have found that OSM's anti-hepatitis C virus (HCV) activity is a new function of this cytokine. OSM synergistically inhibited HCV RNA replication in combination with IFN- α even at a low concentration with weak anti-HCV activity (20% inhibition). OSM may improve the current PEG-IFN- α and RBV therapy for patients with CH C and provide a clue toward understanding the diverse sensitivity to IFN therapy.

2. Materials and methods

2.1. Compounds and antibodies

IFN- α was purchased from Sigma (St. Louis, MO). OSM and IL-31 were purchased from R&D Systems (Minneapolis, MN). IL-6 was purchased from Acris Antibodies (Herford, Germany). LIF was purchased from Chemicon International (Temecula, CA). Anti-HCV core antibody (CP11) was purchased from the Institute of Immunology (Tokyo, Japan), and anti-HCV non-structural 5A (NS5A) antibody was the generous gift of Dr. A. Takamizawa (Research Foundation for Microbial Diseases, Osaka University). Anti- β -actin antibody was purchased from Sigma. Anti-signal transducer and activator of transcription (STAT) 1 and anti-STAT3 antibodies were purchased from BD Bioscience (San Jose, CA). Anti-phospho-STAT1 (Y701) and anti-phospho-STAT3 (Y705) were purchased from Cell Signaling Technology (Danvers, MA).

Abbreviations: SVR, sustained virological response; CH C, chronic hepatitis C; EC₅₀, 50% effective concentration; EMCV, encephalomyocarditis virus; gp130, glycoprotein 130; HCV, hepatitis C virus; PEG-IFN, pegylated-interferon; IL, interleukin; IRES, internal ribosomal entry site; LIF, leukemia-inhibitory factor; NS, non-structural; OSM, oncostatin M; RBV, ribavirin; RL, *Renilla* luciferase; RT-PCR, reverse transcription-polymerase chain reaction; STAT, signal transducer and activator of transcription

* Corresponding author. Fax: +81 86 235 7392.

E-mail address: maikeda@md.okayama-u.ac.jp (M. Ikeda).

2.2. Cell culture

The OR6 cell line is cloned from ORN/C-5B/KE (strain O of genotype 1b) RNA replicating HuH-7 cells, as described previously [9]. OR6c cells are cured OR6 cells from which HCV RNA was eliminated by IFN- α treatment, as previously described [10]. HCV-O/RLGE (strain O) is the authentic HCV RNA containing adaptive mutations of Q1112R, P1115L, E1202G, and K1609E in the NS3 region and replicates efficiently in OR6c cells [11]. Li23 and PH5CH cells were cultured as previously described [12].

2.3. OR6 reporter assay

For the *Renilla* luciferase (RL) assay, 1.5×10^4 OR6 cells were plated onto 24-well plates in triplicate and pre-cultured for 24 h. The cells were treated with OSM and/or IFN- α for 72 h. After the treatment, the cells were harvested with *Renilla* lysis reagent (Promega, Madison, WI) and subjected to RL assay according to the manufacturer's protocol.

2.4. Cell growth assay

To examine OSM's activity in OR6 cell growth, 6.0×10^4 OR6 cells were plated onto 6-well plates in triplicate and were pre-cultured for 24 h. The cells were treated with OSM for 72 h, and then the number of viable cells was counted after trypan blue dye treatment, as previously described [13].

2.5. Reverse transcription and polymerase chain reaction (RT-PCR)

RT-PCR for gp130, OSMR, LIFR, IL6R, IL31RA and glyceraldehyde-3-phosphate dehydrogenase was performed by a method described previously [14]. Briefly, using cellular total RNAs (2 μ g), cDNA was synthesized using M-MLV reverse transcriptase with oligo dT pri-

mer. One-tenth of the synthesized cDNA was subjected to PCR with the specific primer pairs (Supplementary materials).

2.6. Western blot analysis

For Western blot analysis to detect the expression of core and NS5A, 4×10^4 OR6c cells harboring HCV-O/RLGE RNA were plated onto 6-well plates and cultured for 24 h, and then were treated with IFN- α and/or OSM for 72 h. To detect the STATs and phosphorylated STATs, 5×10^5 OR6 cells were plated onto 6-well plates and cultured for 24 h, and then were treated with IFN- α and/or OSM. Preparation of the cell lysates, sodium dodecyl sulfate–polyacrylamide gel electrophoresis and immunoblotting were then performed as previously described [15].

3. Results

3.1. OSM inhibited HCV RNA replication in hepatoma cell line

We have tried to develop differentiated hepatocytes from mesenchymal stem cells using OSM as the differentiation reagent to establish the cell culture system for HCV RNA replication. We tested the reagents needed for differentiation, including OSM, to rule out negative activity for HCV RNA replication. In the course of this procedure, we happened to find that OSM possessed marked anti-HCV activity by using our developed full-length HCV RNA replication reporter system (OR6 assay system) [9]. This system enabled the prompt and precise evaluation of HCV RNA replication levels (Fig. 1A). OSM exhibited marked anti-HCV activity at a low concentration (50% effective concentration (EC_{50}): 0.71 ng/ml) (Fig. 1B) without cytotoxicity (Fig. 1C). OSM's anti-HCV activity was maintained at least until 96 h after a single administration of the reagent (Fig. 1D). These results indicate that OSM possesses anti-HCV activity at a concentration that




Fig. 1. Anti-HCV activity of OSM in HCV RNA replicating OR6 cells. (A) Schematic gene organization of the genome-length HCV RNA replicating in OR6 cells. The position of an adaptive mutation, K1609E, is indicated by a black triangle. (B) OR6 cells were treated with OSM for 72 h and subjected to RL assay. Relative luciferase unit (RLU) was calculated when the RL activity of the control was assigned as 100%. (C) OR6 cells were treated with OSM for 72 h and subjected to a cell viability assay with trypan blue staining. (D) OR6 cells were treated with OSM and harvested at 24, 48, 72, and 96 h and subjected to RL assay.




Fig. 2. The activities of LIF, IL-6 and IL-31 on HCV RNA replication. OR6 cells were treated with LIF (A), IL-6 (B) and IL-31 (C) for 72 h and subjected to RL assay. (D) RNAs from hepatocytes (HuH-7, Li23 and PH5CH) were subjected to RT-PCR with specific primer pairs to gp130, OSMR, LIFR, IL6R, IL31RA and GAPDH.

does not affect cell growth and is a new class of antiviral cytokine.

3.2. Anti-HCV activity of OSM is a unique feature in the IL-6 family

OSM belongs to the IL-6 family, whose members share the common gp130 molecule in each receptor [5]. Therefore, we next examined the activities of other representative IL-6 family members (LIF, IL-6) using the OR6 assay system. As shown in Fig. 2A, LIF had no effect on HCV RNA replication. IL-6 exhibited only a weak anti-HCV activity at the concentration of 10 ng/ml (approximately 20% inhibition) (Fig. 2B).

The OSM receptor consists of gp130 and OSMR [5]. IL31RA is another partner of OSMR and that the heterodimer of these molecules forms a receptor of IL-31 [6]. Therefore, we tried to determine whether or not IL-31 possesses anti-HCV activity in OR6 cells. The result revealed that IL-31 exhibited no anti-HCV activity. Next we examined the expression levels of the receptors in HuH-7, Li23 (a human hepatoma cell line) and PH5CH (an immortalized primary human hepatocyte line). All of these cell lines expressed gp130, OSMR, LIFR and IL6R but not IL31RA (Fig. 2D). The lack of IL31RA expression resulted in IL-31 possessing no anti-HCV activity. These results suggest that OSM's anti-HCV activity seems to be a unique feature among IL-6 family members.

3.3. OSM synergistically enhanced anti-HCV activity of IFN- α

As HCV RNA contains three exogenous genes (RL, Neo and encephalomyocarditis virus (EMCV)-internal ribosomal entry site (IRES)) (Fig. 1A), we tried to determine whether OSM inhibits authentic HCV RNA replication in order to rule out the possibility that OSM's anti-HCV activity is not due to the inhibition of these exogenous genes. OSM inhibited core and NS5A expression in a dose-dependent manner (Fig. 3A, lanes 1–3). We next examined OSM's anti-HCV activity in combination with IFN- α using authentic

HCV-O/RLGE RNA-replicating cells. OSM (1 and 10 ng/ml) drastically inhibited core and NS5A expression in combination with IFN- α (2.5, 5, and 10 IU/ml) (Fig. 3A, lanes 4–12).

OSM exhibited anti-HCV activity even at low concentrations, such as 62 pg/ml, and enhanced the anti-HCV activity of IFN- α (Fig. 3B). We also examined anti-HCV activity of CsA (0, 0.25, 0.5, and 1.0 μ g/ml) alone or in combination with OSM (10 ng/ml) (Supplementary Fig. 1). OSM enhanced CsA's anti-HCV activity. Anti-HCV activity of OSM at 10 ng/ml was almost equal to that of CsA at 0.5 μ g/ml. Then, we performed isobole plot analysis for EC₅₀ of OSM and IFN- α . In Fig. 3C, dotted line means that the interaction of two reagents is evaluated as additive effect (or zero interaction). Points below this line correspond to synergistic interaction (or positive interaction) and points above this line indicate antagonism (or negative interaction) [16]. Therefore, isobole plot analysis of EC₇₀ for OSM and IFN- α revealed that the combination of OSM and IFN- α exhibited striking synergistic inhibition of HCV RNA replication (Fig. 3C). Then we investigated whether or not OSM enhanced the IFN signaling pathway, since OSM activates STATs [17]. A kinetic study regarding the phosphorylation of STAT1 and STAT3 revealed that STAT1 (Y701) was markedly phosphorylated in the early phase within 60 min but that the phosphorylation level was reduced at 120 min (Fig. 3D). On the other hand, the phosphorylation of STAT1 by IFN- α remained consistent until 120 min after treatment (Fig. 3D). The phosphorylation kinetics of STAT3 (Y705) by OSM were consistent until 120 min (Fig. 3D). These results suggest that early-phase activation of STAT1 by OSM may trigger the synergistic activity in HCV RNA replication in combination with IFN- α .

3.4. OSM enhanced anti-HCV activity of IFN- α at even the low effective concentration by itself

As OSM exhibited marked synergistic anti-HCV activity with IFN- α , we tried to determine whether a low concentration of OSM could synergistically enhance the anti-HCV activity of IFN-




Fig. 3. Anti-HCV activity of OSM in combination with IFN- α . (A) HCV-O/RLGE-replicating OR6c cells were treated with OSM in combination with IFN- α for 96 h and subjected to Western blot analysis using anti-core, anti-NS5A and anti- β -actin antibodies. (B) OR6 cells were treated with OSM in combination with IFN- α for 72 h and subjected to RL assay. (C) Isobole plot analysis (EC_{70}) for OSM and IFN- α in OR6 cells after treatment for 72 h. (D) OR6 cells were treated with OSM and IFN- α for 30, 60 and 120 min and subjected to Western blot analysis using anti-STAT1, anti-phospho-STAT1 (Y701), anti-STAT3, anti-phospho-STAT3 (Y705) and anti- β -actin antibodies.

α . For this purpose, we treated OR6 cells with OSM at 25 pg/ml or 50 pg/ml in combination with IFN- α (0, 1, 2, 4, and 8 IU/ml). OSM alone at 25 pg/ml or 50 pg/ml exhibited only 20% inhibitory activ-

ity (Fig. 4A). However, OSM at these concentrations enhanced the anti-HCV activity of IFN- α up to 60% inhibition, when IFN- α at 8 IU/ml was treated with OSM at 25 pg/ml (Fig. 4B). These results




Fig. 4. OR6 cells were treated with OSM and IFN- α for 72 h and subjected to RL assay (A). Relative RL activity was adjusted when the RL activities of the cells treated with only IFN- α were assigned as 100% (B).

indicate that OSM is not only an anti-HCV reagent by itself but also a strong adjuvant for IFN- α 's anti-HCV activity.

4. Discussion

In the present study, we found that OSM possesses anti-HCV activity, which constitutes a new function of this multi-functional cytokine. OSM is involved in liver regeneration and differentiation [7,8]. In the liver, OSM was produced by Kupffer cells [18], and the OSM signal was transmitted via its receptor, which consisted of gp130 and OSMR [5]. The IL-6 family members share gp130 in their receptors; it forms the heterodimer with a unique partner; for example IL6R in IL-6 and LIFR in LIF [2]. We tested the activity of LIF and IL-6 on HCV RNA replication. However, LIF did not exhibit anti-HCV activity, and IL-6 showed only weak anti-HCV activity compared to the OSM. These results suggest that OSM's anti-HCV activity is achieved via OSMR or the combination of gp130 and OSMR rather than via gp130. Recently, it was reported that IL31RA was another partner of OSMR in the IL-31 receptor [6]. If IL-31 could exhibit anti-HCV activity, OSMR seems to be significant in the signal transduction of anti-HCV activity. However, hepatocytes didn't seem to be a natural target of IL-31, because hepatocytes didn't express IL31RA. Further study is needed to clarify OSMR's role in anti-HCV activity.

Isobole plot analysis revealed that OSM exhibited a striking synergistic effect in the anti-HCV activity of IFN- α [19]. This synergistic activity of OSM may be caused by early strong activation of STAT1 by OSM. Furthermore, OSM enhanced the activity of 2'-5' oligoadenylate synthetase promoter in combination with IFN- α (data not shown). These results suggest that STAT1 may be the key player in the synergy between OSM and IFN- α .

In this study, we found OSM's synergistic activity in the anti-HCV activity of IFN- α , when OSM was used at a low concentration (25 pg/ml) with only 20% inhibitory activity against HCV RNA replication. Surprisingly, OSM at 25 pg/ml enhanced the anti-HCV activity of IFN- α by up to 60%. RBV is the only adjuvant to the current PEG-IFN- α therapy for patients with CH C, and the combination therapy of PEG-IFN- α /RBV achieved only approximately 55% of the SVR rate. Therefore, OSM will become a strong partner to the current IFN therapy. As OSM strongly affected the anti-HCV activity of IFN- α , the serum concentration of OSM will affect the SVR in IFN therapy. The future study regarding the relationship between the serum concentration of OSM and SVR may provide a clue toward understanding the resistance to IFN therapy, and the development of OSM as a clinical reagent will serve as a breakthrough in therapy for patients with CH C.

In conclusion, we found OSM's anti-HCV activity a newly identified function of this multifunctional cytokine. The highlight of this study is that OSM exhibited a synergistic effect on the anti-HCV activity of IFN- α even at a low concentration with weak anti-HCV activity by itself.

Acknowledgments

The authors would like to thank Atsumi Morishita and Takashi Nakamura for their technical assistance. This work was supported

by grants-in-aid for a third-term comprehensive 10-year strategy for cancer control and for research on hepatitis from the Ministry of Health, Labor and Welfare of Japan.

Appendix A. Supplementary material

Supplementary data associated with this article can be found, in the online version, at doi:10.1016/j.febslet.2009.03.054.

References

- [1] Fried, M.W. et al. (2002) Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. *New Engl. J. Med.* 347, 975–982.
- [2] Heinrich, P.C., Behrmann, I., Haan, S., Herrmanns, H.M., Muller-Newen, G. and Schaper, F. (2003) Principles of interleukin (IL)-6-type cytokine signalling and its regulation. *Biochem. J.* 374, 1–20.
- [3] Rose, T.M. and Bruce, A.G. (1991) Oncostatin M is a member of a cytokine family that includes leukemia-inhibitory factor, granulocyte colony-stimulating factor, and interleukin 6. *Proc. Natl. Acad. Sci. USA* 88, 8641–8645.
- [4] Zarling, J.M., Shoyab, M., Marquardt, H., Hanson, M.B., Lioubin, M.N. and Todaro, G.J. (1986) Oncostatin M: a growth regulator produced by differentiated histiocytic lymphoma cells. *Proc. Natl. Acad. Sci. USA* 83, 9739–9743.
- [5] Mosley, B., De Imus, C., Friend, D., Boiani, N., Thoma, B., Park, L.S. and Cosman, D. (1996) Dual oncostatin M (OSM) receptors. Cloning and characterization of an alternative signaling subunit conferring OSM-specific receptor activation. *J. Biol. Chem.* 271, 32635–32643.
- [6] Dillon, S.R. et al. (2004) Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice. *Nat. Immunol.* 5, 752–760.
- [7] Hamada, T. et al. (2007) Oncostatin M gene therapy attenuates liver damage induced by dimethylnitrosamine in rats. *Am. J. Pathol.* 171, 872–881.
- [8] Kinoshita, T., Sekiguchi, T., Xu, M.J., Ito, Y., Kamiya, A., Tsuji, K., Nakahata, T. and Miyajima, A. (1999) Hepatic differentiation induced by oncostatin M attenuates fetal liver hematopoiesis. *Proc. Natl. Acad. Sci. USA* 96, 7265–7270.
- [9] Ikeda, M., Abe, K., Dansako, H., Nakamura, T., Naka, K. and Kato, N. (2005) Efficient replication of a full-length hepatitis C virus genome, strain O, in cell culture, and development of a luciferase reporter system. *Biochem. Biophys. Res. Commun.* 329, 1350–1359.
- [10] Ikeda, M., Abe, K., Yamada, M., Dansako, H., Naka, K. and Kato, N. (2006) Different anti-HCV profiles of statins and their potential for combination therapy with interferon. *Hepatology* 44, 117–125.
- [11] Abe, K., Ikeda, M., Dansako, H., Naka, K. and Kato, N. (2007) Cell culture-adaptive NS3 mutations required for the robust replication of genome-length hepatitis C virus RNA. *Virus Res.* 125, 88–97.
- [12] Kato, N., Ikeda, M., Mizutani, T., Sugiyama, K., Noguchi, M., Hirohashi, S. and Shimotohno, K. (1996) Replication of hepatitis C virus in cultured non-neoplastic human hepatocyte. *Jpn. J. Cancer Res.* 87, 787–792.
- [13] Naka, K., Ikeda, M., Abe, K., Dansako, H. and Kato, N. (2005) Mizoribine inhibits hepatitis C virus RNA replication: effect of combination with interferon-alpha. *Biochem. Biophys. Res. Commun.* 330, 871–879.
- [14] Dansako, H., Naganuma, A., Nakamura, T., Ikeda, F., Nozaki, A. and Kato, N. (2003) Differential activation of interferon-inducible genes by hepatitis C virus core protein mediated by the interferon stimulated response element. *Virus Res.* 97, 17–30.
- [15] Kato, N. et al. (2003) Establishment of a hepatitis C virus subgenomic replicon derived from human hepatocytes infected in vitro. *Biochem. Biophys. Res. Commun.* 306, 756–766.
- [16] Suhnel, J. (1990) Evaluation of synergism or antagonism for the combined action of antiviral agents. *Antiviral Res.* 13, 23–39.
- [17] Mahboubi, K. and Pober, J.S. (2002) Activation of signal transducer and activator of transcription 1 (STAT1) is not sufficient for the induction of STAT1-dependent genes in endothelial cells. Comparison of interferon-gamma and oncostatin M. *J. Biol. Chem.* 277, 8012–8021.
- [18] Znoyko, I., Sohara, N., Spicer, S.S., Trojanowska, M. and Reuben, A. (2005) Expression of oncostatin M and its receptors in normal and cirrhotic human liver. *J. Hepatol.* 43, 893–900.
- [19] Yano, M., Ikeda, M., Abe, K., Dansako, H., Ohkoshi, S., Aoyagi, Y. and Kato, N. (2007) Comprehensive analysis of the effects of ordinary nutrients on hepatitis C virus RNA replication in cell culture. *Antimicrob. Agents Chemother.* 51, 2016–2027.

Oxidative Stress Induces Anti-Hepatitis C Virus Status via the Activation of Extracellular Signal-Regulated Kinase

Masahiko Yano,^{1,3} Masanori Ikeda,¹ Ken-ichi Abe,¹ Yoshinari Kawai,^{1,2} Misao Kuroki,¹ Kyoko Mori,¹ Hiromichi Dansako,¹ Yasuo Ariumi,¹ Shougo Ohkoshi,³ Yutaka Aoyagi,³ and Nobuyuki Kato¹

Recently, we reported that β -carotene, vitamin D₂, and linoleic acid inhibited hepatitis C virus (HCV) RNA replication in hepatoma cells. Interestingly, in the course of the study, we found that the antioxidant vitamin E negated the anti-HCV activities of these nutrients. These results suggest that the oxidative stress caused by the three nutrients is involved in their anti-HCV activities. However, the molecular mechanism by which oxidative stress induces anti-HCV status remains unknown. Oxidative stress is also known to activate extracellular signal-regulated kinase (ERK). Therefore, we hypothesized that oxidative stress induces anti-HCV status via the mitogen activated protein kinase (MAPK)/ERK kinase (MEK)–ERK1/2 signaling pathway. In this study, we found that the MEK1/2-specific inhibitor U0126 abolished the anti-HCV activities of the three nutrients in a dose-dependent manner. Moreover, U0126 significantly attenuated the anti-HCV activities of polyunsaturated fatty acids, interferon- γ , and cyclosporine A, but not statins. We further demonstrated that, with the exception of the statins, all of these anti-HCV nutrients and reagents actually induced activation of the MEK–ERK1/2 signaling pathway, which was inhibited or reduced by treatment not only with U0126 but also with vitamin E. We also demonstrated that phosphorylation of ERK1/2 by cyclosporine A was attenuated with *N*-acetylcysteine treatment and led to the negation of inhibition of HCV RNA replication. We propose that a cellular process that follows ERK1/2 phosphorylation and is specific to oxidative stimulation might lead to down-regulation of HCV RNA replication. **Conclusion:** Our results demonstrate the involvement of the MEK–ERK1/2 signaling pathway in the anti-HCV status induced by oxidative stress in a broad range of anti-HCV reagents. This intracellular modulation is expected to be a therapeutic target for the suppression of HCV RNA replication. (HEPATOLOGY 2009;50: 678–688.)

Abbreviations: AA, arachidonic acid; BC, β -carotene; CsA, cyclosporine A; CyPA, cyclophilin A; DHA, docosahexaenoic acid; DMSO, dimethyl sulfoxide; EGF, epidermal growth factor; EPA, eicosapentaenoic acid; ERK, extracellular signal-regulated kinase; FBS, fetal bovine serum; FLV, fluvastatin; HCV, hepatitis C virus; IFN, interferon; LA, linoleic acid; MAPK, mitogen-activated protein kinase; MEK, MAPK/ERK kinase; NS5A, nonstructural 5A; PTV, pitavastatin; PUFA, polyunsaturated fatty acid; RL, renilla luciferase; ROS, reactive oxygen species; VD₂, vitamin D₂; VE, vitamin E.

From the Departments of ¹Tumor Virology and ²Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan; and the ³Division of Gastroenterology and Hepatology, Graduate School of Medical and Dental Sciences, Niigata University, Niigata City, Japan.

Received August 5, 2008; accepted April 8, 2009.

Supported by grants-in-aid for a third-term comprehensive 10-year strategy for cancer control and for research on hepatitis from the Ministry of Health, Labor, and Welfare of Japan. K. A. was supported by a Research Fellowship from the Japan Society for the Promotion of Science for Young Scientists.

Address reprint requests to: Masanori Ikeda, Department of Tumor Virology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Okayama 700-8558, Japan. E-mail: maikedam@md.okayama-u.ac.jp; fax: (81)-86-235-7392.

Copyright © 2009 by the American Association for the Study of Liver Diseases.

Published online in Wiley InterScience (www.interscience.wiley.com).

DOI 10.1002/hep.23026


Potential conflicts of interest: Nothing to report.

Additional Supporting Information may be found in the online version of this article.

Hepatitis C virus (HCV), which belongs to the family Flaviviridae, is a single-stranded positive-sense RNA virus of approximately 9.6 kb.^{1,2} Persistent infection with HCV causes chronic hepatitis, which often leads to liver cirrhosis and hepatocellular carcinoma.³ Therefore, HCV infection is a major health problem worldwide. Interferon (IFN)-based therapies, including the combination of pegylated IFN with ribavirin, are the current standard strategies for chronic hepatitis, but their sustained virological response rates are unsatisfactory.^{4,5} There is thus an urgent need for novel partners with IFN or more effective reagents that may improve the sustained virological response rate.

Following the development in 1999 of a cell culture system to support efficient HCV RNA replication,⁶ numerous studies have identified reagents that inhibit HCV RNA replication and enhance the effect of IFN treatment.^{7–9} Some of these reagents are already available for clinical use. Previously, we also developed a genome-length HCV RNA (strain O of genotype 1b) replication system (OR6) with Renilla luciferase (RL) as a reporter in hepatoma cell lines.¹⁰ Using this OR6 assay system, we found that mizoribine,¹¹ as an immunosuppressant, and

Fig. 1. Schematic gene organization of the genome-length and subgenomic HCV RNA used in this study. ORN/C-5B/KE encoding the RL gene was replicated in OR6 cells and ON/3-5B in sO cells. RL in OR6 cells was expressed as a fusion protein with neomycin phosphotransferase (Neo^R). The arrowhead indicates the position of K1609E, an adaptive mutation.



fluvastatin (FLV) and pitavastatin (PTV),^{9,12} as the reagents for hypercholesterolemia, suppressed genome-length HCV RNA replication. Furthermore, in a recent study¹³ in which we comprehensively analyzed the activities of ordinary nutrients on HCV RNA replication, three nutrients, β -carotene (BC), vitamin D₂ (VD2), and linoleic acid (LA), were found to suppress HCV RNA replication and enhance the antiviral activity of IFN- α or cyclosporine A (CsA) in an additive or a synergistic manner. Because the anti-HCV activities of these three nutrients, as well as CsA, were canceled by treatment with antioxidants such as vitamin E (VE) or selenium, we suggested that oxidative stress might be involved in the anti-HCV activities of these three nutrients and CsA. However, the detailed molecular mechanism via which the oxidative effects of these three nutrients and CsA suppress HCV RNA replication has not been explored.

The production of reactive oxygen species (ROS) plays a pivotal role in various cellular processes, including cell proliferation, differentiation, and apoptosis.¹⁴ Whereas high-level production of ROS resulting from external stimuli is recognized as an important component of the pathogenesis of inflammatory and cancerous diseases, endogenously produced ROS at low concentrations are shown to function as signaling mediators of cellular responses.^{15,16} Emerging evidence indicates that these ROS-triggered responses are mediated primarily via cellular signaling cascades, including a signaling pathway of extracellular signal-regulated kinase (ERK)1/2, namely p44/42 mitogen-activated protein kinase (MAPK), which belongs to the MAPK family.^{17,18}

Several studies have revealed that certain viral proteins initiate activation of the MAPK/ERK kinase (MEK)-ERK1/2 signaling pathway, which may facilitate the viral replication and infectivity in the infected cells.^{19,20} The HCV core protein²¹ and the envelope protein²² have also been reported to up-regulate this signaling pathway. However, another study reported that the HCV non-structural 5A (NS5A) protein suppressed activating protein-1 activation by inhibiting the phosphorylation of

ERK1/2 in replicon cells.²³ Moreover, recent studies using an inhibitor specific to the MEK-ERK1/2 signaling pathway reported that the direct anti-HCV activities of IFN- γ ²⁴ and acetylsalicylic acid²⁵ are mediated in part through the induction of this cascade.

We demonstrate that the activation of MEK-ERK1/2 signaling plays a significant role in the anti-HCV activity caused by oxidative stress in a broad range of anti-HCV reagents.

Materials and Methods

Reagents and Antibodies. Dimethyl sulfoxide (DMSO), BC, VD2, VE, LA, arachidonic acid (AA), eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), and IFN- γ were purchased from Sigma Aldrich (St. Louis, MO), and CsA, FLV, U0126, PD98059, SB203580, and c-Jun N-terminal kinase inhibitor II were obtained from Calbiochem (San Diego, CA). Epidermal growth factor (EGF) was purchased from Toyobo (Osaka, Japan). PTV was purchased from Kowa Company, Ltd. (Tokyo, Japan). Anti-HCV core antibody (CP11) was purchased from the Institute of Immunology (Tokyo, Japan), and anti-HCV NS5A antibody was the generous gift of Dr. A. Takamizawa (Research Foundation for Microbial Diseases, Osaka University). Antibodies specific to ERK1/2 (p44/42 MAPK), MEK1/2, and phosphorylated (S217/221) MEK1/2 were purchased from Cell Signaling Technology (Beverly, MA), and anti-phosphorylated (T202/Y204) ERK1/2 antibody was obtained from BD Biosciences (San Jose, CA). Anti- β -actin antibody was purchased from Sigma Aldrich.

Cell Cultures. The cell lines OR6 and sO were cloned from ORN/C-5B/KE RNA and subgenomic replicon RNA (ON/3-5B)-replicating cells, respectively (Fig. 1). These cells were derived from the hepatoma cell line HuH-7, cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum (FBS), peni-

cillin, streptomycin, and 300 $\mu\text{g}/\text{mL}$ of G418 (Geneticin; Invitrogen, Carlsbad, CA), and passaged twice a week at a 5:1 split ratio. ORN/C-5B/KE and ON/3-5B were derived from HCV-O (strain O of genotype 1b).¹⁰

OR6 Reporter Assay. For the RL assay, $1.0\text{--}1.5 \times 10^4$ OR6 cells were plated onto 24-well plates in triplicate and precultured for 24 hours. The cells were pretreated with DMSO or a specific inhibitor for 1 hour and then were treated with each anti-HCV nutrient or compound in either the absence (DMSO) or presence of a specific inhibitor for 72 hours. After the treatment, the cells were harvested with Renilla lysis reagent (Promega, Madison, WI) and subjected to RL assay according to the manufacturer's protocol.

Western Blot Analysis. For analysis of the effect of a specific inhibitor on the anti-HCV activity, $6.0\text{--}6.5 \times 10^4$ OR6 cells were plated onto 6-well plates and precultured for 24 hours. The pretreatment with DMSO or a specific inhibitor for 1 hour and subsequent treatment for 72 hours was performed in the same manner as for the OR6 reporter assay. For analysis of the activities of each anti-HCV nutrient or reagent on the MEK-ERK1/2 signaling pathway, 1.0×10^5 OR6 or sO cells were plated onto 6-well plates and precultured in 10% FBS-containing medium for 24 hours. After the preculture, the culture medium was changed to FBS-free medium and the cells were cultured for 48 hours prior to treatment with each nutrient or reagent. When the effect of a specific inhibitor or VE on ERK1/2 phosphorylation was analyzed, the cells were pretreated with the specific inhibitor or VE for 1 hour prior to each treatment. Preparation of the cell lysates, sodium dodecyl sulfate-polyacrylamide gel electrophoresis, and immunoblotting were then performed as described.²⁶

Measurement of ROS. OR6 cells in 24-well plates were left untreated or were treated with hydrogen peroxide (1 mM), LA (200 μM), and CsA (15 $\mu\text{g}/\text{mL}$) for 30 minutes and then incubated with dihydrodichlorocarbonylfluorescein diacetate (Invitrogen) (5 μM) for 15 minutes. Fluorescence was measured with a FLUOROSKAN ASCENT fluorescence plate reader (Thermo Fisher Scientific, Waltham, MA) at an excitation wavelength of 485 nm and emission wavelength of 535 nm.

Cell Growth Assay. To examine the activity of EGF on OR6 cell growth, $6.0\text{--}6.5 \times 10^4$ OR6 cells were plated onto 6-well plates in triplicate and were pre-cultured for 24 hours. The cells were treated with or without EGF for 72 hours, and the number of viable cells was counted after trypan blue dye treatment as described.¹¹

Statistical Analysis. Statistical comparison of the luciferase activities between the various treatment groups was performed using the Student *t* test. *P* values of less than 0.05 were considered statistically significant.

Results

Effects of MEK1/2-Specific Inhibitors on the Anti-HCV Activities of BC, VD2, and LA in OR6 Cells.

Our recent study suggested the involvement of oxidative stress in the suppressive mechanism of three anti-HCV nutrients: BC, VD2, and LA.¹³ Because there have been reports of negative regulation of HCV RNA replication via the MEK-ERK1/2 signaling pathway,^{24,25} which is one of the oxidative stress-induced cellular signaling pathways, we hypothesized that the suppression of HCV RNA replication by these three nutrients might be mediated via this cascade (Supporting Fig. 1). To test this hypothesis, we first used an OR6 assay system to examine the effects of U0126 and PD98059, inhibitors specific to MEK1/2, on the three anti-HCV nutrients at 60% inhibitory concentration. As shown in Fig. 2A, treatment with either 5 μM of U0126 or 10 μM of PD98059 slightly enhanced HCV RNA replication in comparison with the control. However, U0126 attenuated the anti-HCV activities of the three nutrients more clearly than PD98059 (Fig. 2A,B). U0126 prevented the anti-HCV activities of the three nutrients in a significant and dose-dependent manner and exerted complete inhibition against the anti-HCV activities of BC and LA (Fig. 2C,D), while the inhibitory effect of PD98059 was more mild (Fig. 2E,F). As shown in Fig. 2G, we also found that U0126 treatment restored the expressions of HCV proteins, core, and NS5A in a dose-dependent manner. We further demonstrated that knockdown of MEK1 or MEK2 by small interfering RNA negated the anti-HCV activity of LA (Supporting Fig. 2A-C). These inhibitions by U0126 against the anti-HCV activities of the three nutrients were not due to the enhancement of encephalomyocarditis virus/internal ribosomal entry site-driven RL activity, because this activity was not increased by U0126 (data not shown). Moreover, treatment with neither SB203580 (an inhibitor specific to p38 MAPK) nor c-Jun N-terminal kinase inhibitor, both of which belong to the same cascade family as MEK-ERK1/2, significantly affected the anti-HCV activities of the three nutrients (data not shown). These results imply that the activation of the MEK-ERK1/2 signaling pathway might be required for the suppression of genome-length HCV RNA replication by the three nutrients in cell culture.

Effect of U0126 on the Suppressive Effects of Polyunsaturated Fatty Acids and Anti-HCV Reagents in OR6 Cells. Previous studies using a cell culture system have shown that polyunsaturated fatty acids (PUFAs), including LA, act as anti-HCV nutrients.^{27,28} A recent study reported that lipid peroxidation of PUFAs was correlated with their anti-HCV activities, which were pre-




Fig. 2. U0126 strongly inhibited the anti-HCV activities of the anti-HCV nutrients BC, VD2, and LA in OR6 cells. (A,B) Effects of MEK-specific inhibitors on the three nutrients at the 60% inhibitory concentration. OR6 cells were pretreated with DMSO, 5 μ M U0126, or 10 μ M PD98059 for 1 hour. The cells were then treated with control medium, 10 μ M BC, 5 μ M VD2, or 50 μ M LA in either the absence (DMSO) or presence of each specific inhibitor for 72 hours. After treatment, RL assay was performed as described in Materials and Methods. Shown here is the relative luciferase activity (%) calculated when the RL activity of the control was assigned as 100%. Data are expressed as the mean \pm standard deviation of triplicate samples from at least three independent experiments. Asterisks indicate significant difference from treatment with DMSO (* P < 0.05; ** P < 0.01; *** P < 0.001; NS, not significant). (A). The ratio of the RL activity in the presence of the MEK-specific inhibitor to the RL activity in the absence of the inhibitor was then calculated (B). (C-F) OR6 reporter assays of the dose effects of MEK1/2-specific inhibitors on the three nutrients. OR6 cells were pretreated with DMSO, U0126 (C), or PD98059 (E) at the indicated concentrations for 1 hour. Treatment of the cells with control medium or each of the three nutrients in either the absence (DMSO) or presence of each specific inhibitor and the RL assay of harvested OR6 cell samples were performed as described in panels A and B. Asterisks indicate significant difference from treatment with DMSO (* P < 0.05; ** P < 0.01; *** P < 0.001; NS, not significant). Next, we calculated the ratio of RL activity in the presence of the MEK-specific inhibitor, U0126 (D), or PD98059 (F), to the RL activity in the absence of the inhibitor. (G) Western blot analysis of the dose effects of U0126 on three nutrients. OR6 cells were pretreated and then treated as in panel C. The production of HCV core and NS5A in the cells was analyzed by way of immunoblotting using antibodies specific to HCV core (top row) and NS5A (middle row). β -actin was used as a control for the amount of protein loaded per lane (bottom row).

vented by treatment with VE.²⁹ This result coincides with our previous observations on the effects of LA.¹³ We proposed that the MEK–ERK1/2 signaling pathway might be involved in the anti-HCV activity of PUFAs, including LA, because lipid peroxidation is known to be a ROS-triggered cellular modification.¹⁶ As expected, treatment with U0126 attenuated the anti-HCV activities of four representative PUFAs in a significant and dose-dependent manner (Fig. 3A,B).

Moreover, because the anti-HCV activities of BC, VD2, LA, and CsA, but not FLV, were found to be negated by VE,¹³ we were also interested in the potent role of the MEK–ERK1/2 signaling pathway in the anti-HCV mechanism of CsA. Furthermore, the previous study using a subgenomic replicon system had already shown the partial involvement of this cascade in the antiviral activity of IFN- γ .²⁴ Therefore, we examined the effects of U0126 on various anti-HCV reagents: IFN- γ , CsA, and statins (FLV and PTV). We confirmed that also in genome-length HCV RNA replication cells, U0126 significantly inhibited the anti-HCV activity of IFN- γ (Fig. 3C,D). Interestingly, consistent with the effects of treatment with VE,¹³ the anti-HCV activity of CsA was completely abrogated by U0126 in a significant and dose-dependent manner, whereas statins were unaffected (Fig. 3C,D).

U0126 restored the reduced expression of HCV proteins by PUFAs, IFN- γ , and CsA in a dose-dependent manner, whereas statins were unaffected (Fig. 3E,F). These results were supported by additional real-time reverse-transcription polymerase chain reaction and immunofluorescence analyses (Supporting Fig. 3A-C). We also observed that knockdown of MEK1 or MEK2 by small interfering RNA did not affect the anti-HCV activity of PTV (Supporting Fig. 2A-C). Collectively, these findings suggest that the MEK–ERK1/2 signaling pathway may play a critical role in the negative regulation of HCV RNA replication by the anti-HCV nutrients BC and VD2, PUFAs, and the anti-HCV reagents IFN- γ and CsA, but not statins.

Activation of the MEK–ERK1/2 Signaling Pathway by Anti-HCV Nutrients and Reagents. To further ensure the involvement of the MEK–ERK1/2 signaling pathway in the suppressive mechanisms of anti-HCV nutrients and reagents, we next examined whether these nutrients and reagents could actually initiate the activation of this signaling pathway. After treating the HCV RNA replicating cells with each of the nutrients and reagents, we performed immunoblotting specific to the phosphorylation of ERK1/2 and MEK1/2. In the same way as EGF, a potent activator of these kinases, the three anti-HCV nutrients (BC, VD2, and LA) enhanced the phosphorylation of ERK1/2 and MEK1/2 in both genome-

length and subgenomic HCV RNA replication cells (Fig. 4A,B). IFN- γ , CsA, and all of the PUFAs also up-regulated this cascade in OR6 cells (Fig. 4C,D). The increase in phosphorylation of ERK1/2 was not observed after either statin treatment (Fig. 4D). The activation of MEK–ERK1/2 by the three anti-HCV nutrients was apparent until 1 hour after their application and subsequently attenuated, although EGF exhibited persistent enhancement of MEK–ERK1/2 phosphorylation (Fig. 4E). Because the experiments regarding ERK1/2 phosphorylation were performed in FBS-free conditions, we checked the anti-HCV activity of PTV, CsA, and LA in FBS-free medium. The results revealed that these anti-HCV reagents and nutrients also inhibited HCV RNA replication in FBS-free conditions (Supporting Fig. 4). Taken together, these findings indicate that the anti-HCV nutrients and reagents activated the MEK–ERK1/2 signaling pathway in HCV RNA replicating cells, providing further confirmation that this signaling cascade might be involved in their anti-HCV activities.

MEK1/2-Specific Inhibitors Attenuated the Increased Phosphorylation of ERK1/2 by Anti-HCV Nutrients/Reagents and EGF. We next tested whether MEK1/2-specific inhibitors could prevent not only the suppression of HCV RNA replication but also the activation of ERK1/2 by the anti-HCV nutrients BC, VD2, and PUFAs and the anti-HCV reagents IFN- γ and CsA. Consistent with the inhibitory effects on their anti-HCV activities, U0126 more markedly abrogated the increase in ERK1/2 phosphorylation by anti-HCV nutrients, reagents, and EGF than did PD98059 (Fig. 5A,B). As shown in Fig. 5C, the enhanced ERK1/2 phosphorylation by the three nutrients and EGF was reduced by U0126 in a dose-dependent manner.

VE Attenuated the Increased Phosphorylation of ERK1/2 by Anti-HCV Nutrients/Reagents and EGF. Because the suppression of HCV RNA replication by BC, VD2, LA, and CsA were completely negated by the treatment with VE in our recent study,¹³ we investigated whether VE could also inhibit ERK1/2 activation by anti-HCV nutrients and reagents. As expected, VE also attenuated the enhanced phosphorylation of ERK1/2 by not only anti-HCV nutrients and CsA but also IFN- γ and EGF (Fig. 6A,B). We also demonstrated that phosphorylation of ERK1/2 by CsA was attenuated with *N*-acetylcysteine treatment and led to the negation of inhibition of HCV RNA replication (Supporting Fig. 5A-C). The anti-HCV nutrients and reagents, whose activities were negated by U0126, were also inhibited by VE. In contrast, the anti-HCV activities of statins were not negated by U0126 or VE. We also demonstrated that LA and CsA induce ROS (Fig.




Fig. 3. U0126 dose-dependently attenuated the anti-HCV activities of PUFAs, IFN-γ, and CsA, but not the statins. (A-D) OR6 reporter assays of the dose effects of U0126 on the PUFAs and anti-HCV reagents at the 60% inhibitory concentration. OR6 cells were pretreated with DMSO or U0126 as in Fig. 2C and then treated with control medium, 30 μM AA, 45 μM EPA, 45 μM DHA, or 50 μM LA (A) and control medium, 0.4 IU/mL IFN-γ, 0.2 μg/mL CsA, 3 μM FLV, or 1 μM PTV (C), respectively, in either the absence (DMSO) or presence of U0126 for 72 hours. After the treatment, the RL assay of harvested OR6 cell samples was performed as described in Fig. 2A and 2B. Asterisks indicate significant difference from treatment with DMSO (*P < 0.05; **P < 0.01; NS, not significant). The ratio of the RL activity in the presence of U0126 to the RL activity in the absence of U0126 was then calculated (B, D). (E, F) Western blot analysis of the dose effects of U0126 on the PUFAs and anti-HCV reagents. The production of HCV core (top row) and NS5A (middle row) in the cells treated as in panel A (E) and panel C (F) was analyzed as described in Fig. 2G. β-actin was used as a control for the amount of protein loaded per lane (bottom row).




Fig. 4. U0126 attenuated the MEK-ERK1/2 signaling pathway activated by anti-HCV nutrients and reagents. (A, B) Three anti-HCV nutrients—BC, VD2, and LA—increased the phosphorylation of MEK-ERK1/2 in both full-length and subgenomic HCV RNA replication cells. OR6 cells (A) or s0 cells (B) were maintained in FBS-free medium for 48 hours and then treated with control medium, 20 μ M BC, 10 μ M VD2, 100 μ M LA, or 50 ng/mL EGF for 15 minutes. After treatment, cell lysates underwent western blot analysis using antibodies specific to phosphorylated ERK1/2, ERK1/2, phosphorylated MEK1/2, and MEK1/2. The appropriate expression of HCV core and NS5A was determined by way of immunoblotting with their respective antibodies. (C, D) IFN- γ , CsA, and the PUFAs, but not the statins, increased the phosphorylation of MEK-ERK1/2 in OR6 cells. OR6 cells were precultured as described in panels A and B, then treated with control medium, 100 μ M AA, EPA, DHA, or LA, or 50 ng/mL EGF (C) and control medium, 2 IU/mL IFN- γ , 2 μ g/mL CsA, 5 μ M of FLV or PTV, or 50 ng/mL EGF (D), respectively, for 15 minutes. (E) Time-course western blot analysis of the increase of MEK-ERK1/2 phosphorylation by the three anti-HCV nutrients and EGF. Samples for analysis were harvested prior to treatment with the control medium, 20 μ M BC, 10 μ M VD2, 100 μ M LA, or 50 ng/mL EGF (0 time point) and at 15, 60, and 120 minutes posttreatment. After all of the treatments (C-E), cell lysates were subjected to western blot analysis of the activation of the MEK-ERK1/2 signaling pathway as described in panels A and B. β -actin was used as a control for the amount of protein loaded per lane in all analyses.




Fig. 5. U0126 strongly abolished ERK1/2 phosphorylation by the anti-HCV nutrients, anti-HCV reagents, and EGF. (A,B) Effects of the MEK1/2-specific inhibitors on ERK1/2 phosphorylation by anti-HCV nutrients and reagents. OR6 cells were precultured as described in Figs. 4A and B, and then pretreated with DMSO (–), 10 μ M U0126: (U), or 20 μ M PD98059: (P) for 1 hour. Subsequently, the cells were treated with control medium, 20 μ M BC, 10 μ M VD2, or 100 μ M LA (A) and control medium, 100 μ M AA, 2 IU/mL IFN- γ , 2 μ g/mL CsA, or 50 ng/mL EGF (B), respectively, in either the absence (DMSO) (–) or presence of U0126 (U) or PD98059 (P) for 15 minutes. (C) Dose effects of U0126 on ERK1/2 phosphorylation by the three anti-HCV nutrients and EGF. OR6 cells were precultured as described in Figs. 4A and 4B, then pretreated with DMSO (–) or 5 or 10 μ M U0126 for 1 hour. The cells were then treated with control medium, 20 μ M BC, 10 μ M VD2, 100 μ M LA, or 50 ng/mL EGF in either the absence (–) or presence of U0126 for 15 minutes. After all treatments (A–C), cell lysates were subjected to western blot analysis using antibodies specific to phosphorylated ERK1/2 (top row) and ERK1/2 (middle row). β -actin was used as a control for the amount of protein loaded per lane (bottom row).

7). Collectively, these results suggest that these nutrients and reagents induce ROS as an oxidant in HCV RNA replicating cells, leading to activation of the MEK–ERK1/2 signaling pathway and suppression of HCV RNA replication.

The Effects of EGF on HCV RNA Replication were Different than Those of the Anti-HCV Nutrients/Reagents. Because the study by Huang et al.²⁴ showed that EGF time-dependently suppressed the expressions of HCV nonstructural proteins in subgenomic replicon-harboring cells, we wondered whether EGF could suppress genome-length HCV RNA replication. EGF inhibited HCV RNA replication by approximately 25% at a concentration of 100 ng/mL. This anti-HCV activity was weaker than that of the anti-HCV nutrients and reagents

tested in this study. However, as shown in the cell growth assay, EGF promoted OR6 cell proliferation in a dose-dependent manner (Supporting Fig. 6). These cell growth effects of EGF may have caused us to underestimate the actual anti-HCV activity of EGF. The other reagents and nutrients did not affect cell proliferation compared with EGF (Supporting Fig. 7).

Discussion

The previous studies using the MEK1/2-specific inhibitor and subgenomic replicon system showed that induction of the MEK–ERK1/2 signaling pathway might be required for the suppression of HCV RNA replication by some reagents.^{24,25} In agreement with the study by Huang




Fig. 6. VE attenuated ERK1/2 phosphorylation by the anti-HCV nutrients and reagents. OR6 cells were precultured as described in Figs. 4A and B, and then pretreated with ethanol (-) or 50 μ M VE (+) for 1 hour. The cells were then treated with control medium, 20 μ M BC, 10 μ M VD2, 100 μ M LA, or 50 ng/mL EGF (A) and control medium, 100 μ M AA, 2 IU/mL IFN- γ , and 2 μ g/mL CsA (B), respectively, in either the absence (ethanol) (-) or presence (+) of 50 μ M VE for 15 minutes. After the treatment, cell lysates underwent western blot analysis as described in Fig. 5.

et al.,²⁴ we also confirmed that U0126 inhibited the anti-HCV activity of IFN- γ in OR6 cells stably replicating genome-length HCV RNA. Although they did not identify the direct activation of the MEK-ERK1/2 signaling pathway by IFN- γ , we demonstrated that IFN- γ could stimulate this cascade in HCV RNA replication cells. Moreover, this stimulation was not only inhibited by U0126 but also by antioxidant VE. This result indicates the involvement of oxidative stress in the anti-HCV activity of IFN- γ as well as the MEK-ERK1/2 signaling pathway. IFNs induce the transcription of IFN-stimulated genes through the JAK-STAT pathway, but the induction of IFN-stimulated genes by IFN- γ has been far more complex than that by IFN type I.³⁰ A study using a

macrophage cell line revealed that IFN- γ activated ERK1/2, followed by the expression of IFN- γ -stimulated genes downstream of the JAK-STAT signaling pathway.³¹ Another study reported that the defensive activity of IFN- γ against hepatitis B virus in hepatoblastoma cells was mediated through the induction of oxidative stress.³² Furthermore, ROS itself has been reported to suppress HCV RNA replication in human hepatoma cells.³³ These reports support our proposal regarding anti-HCV activity of oxidative stress that the generation of intracellular ROS inhibits HCV RNA replication through activation of the MEK-ERK1/2 signaling pathway. Waris and Siddiqui³⁴ reported that calcium-dependent ROS generation induced cyclooxygenase-2 and prostaglandin E(2) via the activation of nuclear factor kappa B, leading to the suppression of HCV RNA replication. Choi et al.³⁵ also demonstrated that elevated calcium suppressed HCV RNA replication. The activation of nuclear factor kappa B by ROS was mediated through the MEK-ERK1/2 signaling pathway. Therefore, we suggest that the oxidative reagents and nutrients in this study also may induce anti-HCV status by calcium-dependent ROS generation.

In the course of our study of the anti-HCV activities of these three nutrients, we found that treatment with U0126 more strongly inhibited their anti-HCV activities than treatment with PD98059. U0126 has been shown to possess approximately 100-fold-higher MEK1/2-specific inhibitory activity than PD98059.³⁶ This different potential between the two inhibitors was considered to cause a gap in their effects on anti-HCV activities. We further found that, much like EGF, all three nutrients enhanced the phosphorylation of ERK1/2 and MEK1/2, which was reduced by treatment with U0126 or VE. In addition, the




Fig. 7. ROS production by H₂O₂, LA, and CsA. OR6 cells were untreated or treated with H₂O₂ (1 mM), LA (200 μ M), and CsA (15 μ g/mL) and then incubated with dihydrodichlorocarbonyfluorescein diacetate. Fluorescence was measured with a fluorescence plate reader. ***P* < 0.01 versus untreated cells.

present study was the first to observe that BC, which has been shown to produce ROS,³⁷ activates the MEK–ERK1/2 signaling pathway, an action that VD2³⁸ and LA³⁹ have already been shown to exhibit in leukemia cell and dendritic cell lines, respectively. Furthermore, we found the involvement of the MEK–ERK1/2 signaling pathway in the anti-HCV mechanism of the three nutrients as well as various PUFAs, which were reported to be mediated through lipid peroxidation.²⁹ These results suggest that the anti-HCV nutrients BC, VD2, and PUFAs, including LA, as well as IFN- γ may suppress HCV RNA replication via activation of the MEK–ERK1/2 signaling pathway in response to ROS production.

We also investigated the involvement of the MEK–ERK1/2 signaling pathway in the suppressive mechanism of anti-HCV reagents other than IFN- γ . In our previous study, the anti-HCV activity of CsA, but not FLV, was prevented by VE.¹³ Consequently, these results implied that CsA, but not statins, could be potent activators of the MEK–ERK1/2 signaling pathway as oxidants, leading to down-regulation of HCV RNA replication. CsA has been demonstrated to bind to cyclophilins and suppress HCV RNA replication by abolishing their interaction with NS5B polymerase.⁴⁰ This CsA binding to cyclophilins, especially cyclophilin A (CyPA), has been shown to result in the generation of ROS through inhibition of the peptidylprolyl-cis-trans-isomerase-like activity of CyPA.⁴¹ Moreover, CyPA was reported to be secreted in response to oxidative stress,⁴² and to bind to a cell surface receptor, CD147, followed by ERK1/2 activation.⁴³ These reports and our results suggest that CsA, acting as an oxidant, may trigger activation of the MEK–ERK1/2 signaling pathway, both directly by producing ROS by way of interaction with CyPA in the early phase, and indirectly by secreting CyPA in the late phase. Both activations could lead to an inhibition of HCV RNA replication. Thus, CyPA may play a critical role as an intermedial in the oxidative anti-HCV activity of CsA. In the latest study, CyPA was identified as the most essential cellular cofactor of HCV RNA replication among cyclophilins.⁴⁴ Further studies will be needed to clarify whether CyPA is required for the oxidative suppressive mechanism of anti-HCV nutrients/reagents other than CsA.

Although we expected that strong activation of the MEK–ERK1/2 signaling pathway would suppress HCV RNA replication, EGF exhibited only slight anti-HCV activity in OR6 cells. The promotion of cell growth by EGF might prevent its primary inhibitory effect on HCV RNA replication. A portion of the ERK1/2 phosphorylation by EGF was also reduced by treatment with VE (Fig. 6A), suggesting that EGF might stimulate the MEK–ERK1/2 signaling pathway, in part, as an oxidant, and

that this oxidative activity of EGF could exhibit its slight anti-HCV activity.

In this study, using MEK1/2 specific inhibitors, we revealed that the MEK–ERK1/2 signaling pathway is involved in the oxidative antiviral mechanism of the anti-HCV nutrients BC, VD2, and PUFAs and the anti-HCV reagents IFN- γ and CsA. Our results suggest that this oxidative induction of the MEK–ERK1/2 signaling pathway could be a novel therapeutic strategy for the eradication of HCV infection. Although oxidants themselves cause liver damage, they may work as anti-HCV factors during therapy in patients with chronic hepatitis C.

In conclusion, this study suggests that the anti-HCV activity of oxidative stress is closely linked to the activation of the MEK–ERK1/2 signaling pathway.

Acknowledgment: The authors thank Atsumi Morishita for technical assistance.

References

1. Kato N, Hijikata M, Ootsuyama Y, Nakagawa M, Ohkoshi S, Sugimura T, et al. Molecular cloning of the human hepatitis C virus genome from Japanese patients with non-A, non-B hepatitis. *Proc Natl Acad Sci U S A* 1990;87:9524-9528.
2. Robertson B, Myers G, Howard C, Bretin T, Bukh J, Gaschen B, et al. Classification, nomenclature, and database development for hepatitis C virus (HCV) and related viruses: proposals for standardization. International Committee on Virus Taxonomy. *Arch Virol* 1998;143:2493-2503.
3. Liang T, Jeffers L, Reddy K, De Medina M, Parker I, Cheinquer H, et al. Viral pathogenesis of hepatocellular carcinoma in the United States. *HEPATOLOGY* 1993;18:1326-1333.
4. Hadziyannis S, Sette HJ, Morgan T, Balan V, Diago M, Marcellin P, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. *Ann Intern Med* 2004;140:346-355.
5. McHutchison J, Fried M. Current therapy for hepatitis C: pegylated interferon and ribavirin. *Clin Liver Dis* 2003;7:149-161.
6. Lohmann V, Körner F, Koch J, Herian U, Theilmann L, Bartenschlager R. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. *Science* 1999;285:110-113.
7. Watashi K, Hijikata M, Hosaka M, Yamaji M, Shimotohno K. Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes. *HEPATOLOGY* 2003;38:1282-1288.
8. Klumpp K, Lévesque V, Le Pogam S, Ma H, Jiang W, Kang H, et al. The novel nucleoside analog R1479 (4'-azidocytidine) is a potent inhibitor of NS5B-dependent RNA synthesis and hepatitis C virus replication in cell culture. *J Biol Chem* 2006;281:3793-3799.
9. Ikeda M, Abe K, Yamada M, Dansako H, Naka K, Kato N. Different anti-HCV profiles of statins and their potential for combination therapy with interferon. *HEPATOLOGY* 2006;44:117-125.
10. Ikeda M, Abe K, Dansako H, Nakamura T, Naka K, Kato N. Efficient replication of a full-length hepatitis C virus genome, strain O, in cell culture, and development of a luciferase reporter system. *Biochem Biophys Res Commun* 2005;329:1350-1359.
11. Naka K, Ikeda M, Abe K, Dansako H, Kato N. Mizoribine inhibits hepatitis C virus RNA replication: effect of combination with interferon-alpha. *Biochem Biophys Res Commun* 2005;330:871-879.
12. Ikeda M, Kato N. Life style-related diseases of the digestive system: cell culture system for the screening of anti-hepatitis C virus (HCV) reagents: suppression of HCV replication by statins and synergistic action with interferon. *J Pharmacol Sci* 2007;105:145-150.

13. Yano M, Ikeda M, Abe K, Dansako H, Ohkoshi S, Aoyagi Y, et al. Comprehensive analysis of the effects of ordinary nutrients on hepatitis C virus RNA replication in cell culture. *Antimicrob Agents Chemother* 2007;51:2016-2027.
14. England K, Cotter T. Direct oxidative modifications of signalling proteins in mammalian cells and their effects on apoptosis. *Redox Rep* 2005;10:237-245.
15. Sundaresan M, Yu Z, Ferrans V, Irani K, Finkel T. Requirement for generation of H₂O₂ for platelet-derived growth factor signal transduction. *Science* 1995;270:296-299.
16. Balboa M, Balsinde J. Oxidative stress and arachidonic acid mobilization. *Biochim Biophys Acta* 2006;1761:385-391.
17. Aikawa R, Komuro I, Yamazaki T, Zou Y, Kudoh S, Tanaka M, et al. Oxidative stress activates extracellular signal-regulated kinases through Src and Ras in cultured cardiac myocytes of neonatal rats. *J Clin Invest* 1997;100:1813-1821.
18. Czaja M, Liu H, Wang Y. Oxidant-induced hepatocyte injury from menadione is regulated by ERK and AP-1 signaling. *HEPATOLOGY* 2003;37:1405-1413.
19. Yang X, Gabuzda D. Regulation of human immunodeficiency virus type 1 infectivity by the ERK mitogen-activated protein kinase signaling pathway. *J Virol* 1999;73:3460-3466.
20. Kong X, San Juan H, Behera A, Peoples M, Wu J, Lockey R, et al. ERK-1/2 activity is required for efficient RSV infection. *FEBS Lett* 2004;559:33-38.
21. Tsutsumi T, Suzuki T, Moriya K, Shintani Y, Fujie H, Miyoshi H, et al. Hepatitis C virus core protein activates ERK and p38 MAPK in cooperation with ethanol in transgenic mice. *HEPATOLOGY* 2003;38:820-828.
22. Zhao L, Wang L, Ren H, Cao J, Li L, Ke J, et al. Hepatitis C virus E2 protein promotes human hepatoma cell proliferation through the MAPK/ERK signaling pathway via cellular receptors. *Exp Cell Res* 2005;305:23-32.
23. Macdonald A, Crowder K, Street A, McCormick C, Saksela K, Harris M. The hepatitis C virus non-structural NS5A protein inhibits activating protein-1 function by perturbing ras-ERK pathway signaling. *J Biol Chem* 2003;278:17775-17784.
24. Huang Y, Chen X, Konduri M, Fomina N, Lu J, Jin L, et al. Mechanistic link between the anti-HCV effect of interferon gamma and control of viral replication by a Ras-MAPK signaling cascade. *HEPATOLOGY* 2006;43:81-90.
25. Trujillo-Murillo K, Rincón-Sánchez A, Martínez-Rodríguez H, Bosques-Padilla F, Ramos-Jiménez J, Barrera-Saldaña H, et al. Acetylsalicylic acid inhibits hepatitis C virus RNA and protein expression through cyclooxygenase 2 signaling pathways. *HEPATOLOGY* 2008;47:1462-1472.
26. Kato N, Sugiyama K, Namba K, Dansako H, Nakamura T, Takami M, et al. Establishment of a hepatitis C virus subgenomic replicon derived from human hepatocytes infected in vitro. *Biochem Biophys Res Commun* 2003;306:756-766.
27. Leu G, Lin T, Hsu J. Anti-HCV activities of selective polyunsaturated fatty acids. *Biochem Biophys Res Commun* 2004;318:275-280.
28. Kapadia S, Chisari F. Hepatitis C virus RNA replication is regulated by host geranylgeranylation and fatty acids. *Proc Natl Acad Sci U S A* 2005;102:2561-2566.
29. Huang H, Chen Y, Ye J. Inhibition of hepatitis C virus replication by peroxidation of arachidonate and restoration by vitamin E. *Proc Natl Acad Sci U S A* 2007;104:18666-18670.
30. Sen G, Ransohoff R. Interferon-induced antiviral actions and their regulation. *Adv Virus Res* 1993;42:57-102.
31. Hu J, Roy S, Shapiro P, Rodig S, Reddy S, Platanius L, et al. ERK1 and ERK2 activate CCAAAT/enhancer-binding protein-beta-dependent gene transcription in response to interferon-gamma. *J Biol Chem* 2001;276:287-297.
32. Togashi H, Ohno S, Matsuo T, Watanabe H, Saito T, Shinzawa H, et al. Interferon-gamma, tumor necrosis factor-alpha, and interleukin 1-beta suppress the replication of hepatitis B virus through oxidative stress. *Res Commun Mol Pathol Pharmacol* 2000;107:407-417.
33. Choi J, Lee K, Zheng Y, Yamaga A, Lai M, Ou J. Reactive oxygen species suppress hepatitis C virus RNA replication in human hepatoma cells. *HEPATOLOGY* 2004;39:81-89.
34. Waris G, Siddiqui A. Hepatitis C virus stimulates the expression of cyclooxygenase-2 via oxidative stress: role of prostaglandin E2 in RNA replication. *J Virol* 2005;79:9725-9734.
35. Choi J, Forman H, Ou J, Lai M, Scronello S, Nandipati A. Redox modulation of hepatitis C virus replication complex is calcium dependent. *Free Radical Biol Med* 2006;41:1488-1498.
36. Favata M, Horiuchi K, Manos E, Daulerio A, Stradley D, Feeser W, et al. Identification of a novel inhibitor of mitogen-activated protein kinase kinase. *J Biol Chem* 1998;273:18623-18632.
37. Paolini M, Antelli A, Pozzetti L, Spetlova D, Perocco P, Valgimigli L, et al. Induction of cytochrome P450 enzymes and over-generation of oxygen radicals in beta-carotene supplemented rats. *Carcinogenesis* 2001;22:1483-1495.
38. Ji Y, Kutner A, Verstuyf A, Verlinden L, Studzinski G. Derivatives of vitamins D2 and D3 activate three MAPK pathways and upregulate pRb expression in differentiating HL60 cells. *Cell Cycle* 2002;1:410-415.
39. Loscher C, Draper E, Leavy O, Kelleher D, Mills K, Roche H. Conjugated linoleic acid suppresses NF-kappa B activation and IL-12 production in dendritic cells through ERK-mediated IL-10 induction. *J Immunol* 2005;175:4990-4998.
40. Watashi K, Ishii N, Hijikata M, Inoue D, Murata T, Miyanari Y, et al. Cyclophilin B is a functional regulator of hepatitis C virus RNA polymerase. *Mol Cell* 2005;19:111-122.
41. Hong F, Lee J, Song J, Lee S, Ahn H, Cho J, et al. Cyclosporin A blocks muscle differentiation by inducing oxidative stress and inhibiting the peptidyl-prolyl-cis-trans isomerase activity of cyclophilin A: cyclophilin A protects myoblasts from cyclosporin A-induced cytotoxicity. *FASEB J* 2002;16:1633-1635.
42. Jin Z, Melaragno M, Liao D, Yan C, Haendeler J, Suh Y, et al. Cyclophilin A is a secreted growth factor induced by oxidative stress. *Circ Res* 2000;87:789-796.
43. Yurchenko V, Zybarth G, O'Connor M, Dai W, Franchin G, Hao T, et al. Active site residues of cyclophilin A are crucial for its signaling activity via CD147. *J Biol Chem* 2002;277:22959-22965.
44. Yang F, Robotham J, Nelson H, Irsigler A, Kenworthy R, Tang H. Cyclophilin A is an essential cofactor for hepatitis C virus infection and the principal mediator of cyclosporine A resistance in vitro. *J Virol* 2008;82:5269-5278.



Efficient replication systems for hepatitis C virus using a new human hepatoma cell line

Nobuyuki Kato^{a,*}, Kyoko Mori^a, Ken-ichi Abe^a, Hiromichi Dansako^a, Misao Kuroki^a, Yasuo Ariumi^a, Takaji Wakita^b, Masanori Ikeda^a

^a Department of Tumor Virology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Okayama 700-8558, Japan

^b Department of Virology II, National Institute of Infectious Diseases, 1-23-1 Toyama, Shinjuku-ku, Tokyo 162-8640, Japan

ARTICLE INFO

Article history:

Received 29 May 2009

Received in revised form 12 August 2009

Accepted 21 August 2009

Available online 29 August 2009

Keywords:

Hepatitis C virus (HCV)

HCV RNA replication

Li23 cells

Reporter assay for anti-HCV reagents

Infectious HCV production

ABSTRACT

Persistent hepatitis C virus (HCV) infection causes chronic liver diseases and is a serious global health problem. Cell culture-based persistent HCV RNA replication systems and infectious HCV production systems are widely used in HCV research. However, persistent HCV production systems have been developed only for HuH-7 hepatoma cells. Here we found a new human hepatoma cell line, Li23, that enables persistent HCV production and anti-HCV reagent assay. Li23's cDNA expression profile differed from HuH-7's, although the two cells had similar liver-specific expression profiles. We used HCV RNA with a specific combination of adaptive mutations to develop an HCV replicon system and genome-length HCV RNA replicating systems including a reporter assay system. Finally, Li23-derived cells persistently produced infectious virus of an HCV strain. Li23-derived cells are potentially useful for understanding the HCV life cycle and for finding antiviral targets.

© 2009 Elsevier B.V. All rights reserved.

1. Introduction

Hepatitis C virus (HCV) infection frequently causes active liver diseases such as chronic hepatitis, cirrhosis, and hepatocellular carcinoma (Choo et al., 1989; Saito et al., 1990; Thomas, 2000). Although the combination of pegylated-interferon (PEG-IFN) and ribavirin is the standard therapy worldwide, only half of the patients receiving this treatment exhibit a sustained virological response (Chevaliez and Pawlotsky, 2007; Hadziyannis et al., 2004). Since more than 170 million people are infected with HCV worldwide, the virus remains a serious global health problem (Thomas, 2000). HCV is an enveloped positive single-stranded RNA virus of the *Flaviviridae* family. The HCV RNA genome encodes a large polyprotein precursor of approximately 3000 amino acids, which is cleaved into 10 proteins in the following order: core, envelope 1 (E1), E2, p7, non-structural 2 (NS2), NS3, NS4A, NS4B, NS5A, and NS5B (Hijikata et al., 1991, 1993; Kato et al., 1990). Although many issues have been addressed since HCV was first identified, the lack of a virus culture system has long been a serious handicap in

the fight against HCV infection (Kato and Shimotohno, 2000). The development of an HCV replicon system enabling HCV subgenomic RNA replication in HuH-7 human hepatoma cells has allowed the study of the mechanisms underlying HCV replication (Lohmann et al., 1999). After the first replicon of genotype 1b was developed, HCV replicons derived from several HCV strains appeared, and tissue, genotype, and host ranges were expanded (Ali et al., 2004; Date et al., 2004; Ikeda et al., 2002; Kato et al., 2003a,b; Kishine et al., 2002; Zhu et al., 2003). However, most of RNA replication systems using the culture cells other than HuH-7 cells have been fairly low-level. Furthermore, genome-length HCV RNA replication systems and drug assay systems have been developed (Blight et al., 2002; Ikeda et al., 2002, 2005; Mori et al., 2008; Pietschmann et al., 2002). To date, however, robust genome-length HCV RNA replication and anti-HCV reagent assays have been developed for only one human cell line, HuH-7 (Bartenschlager and Sparacio, 2007; Lindenbach and Rice, 2005). In 2005, an efficient virus production system using the JFH1 genotype 2a strain was developed using HuH-7-derived cell lines (Lindenbach et al., 2005; Wakita et al., 2005; Zhong et al., 2005). In this system also, HuH-7 is still the only cell line that enables persistent HCV production without additional host factors such as CD81 (Gottwein and Bukh, 2008), although transient virus production in human hepatoma cell line LH86 was recently reported (Zhu et al., 2007). Furthermore, it is uncertain whether or not the recent advances obtained from the HuH-7 cell system reflect the general features of the HCV life cycle. Here, we found a new human hepatoma cell line, Li23, that enables robust genome-length

Abbreviations: HCV, hepatitis C virus; PEG-IFN, pegylated-interferon; E1, envelope 1; NS2, non-structural 2; RT-PCR, reverse transcription-polymerase chain reaction; PBS, phosphate-buffered saline; p.i., post-infection; dsRNA, double-stranded RNA; EC₅₀, 50% effective concentration.

* Corresponding author. Tel.: +81 86 235 7385; fax: +81 86 235 7392.

E-mail address: nkato@md.okayama-u.ac.jp (N. Kato).

HCV RNA replication. Using Li23-derived cell lines, we developed a novel drug assay system and a persistent HCV production system.

2. Materials and methods

2.1. Cell line

The Li23 cell line, established in 1987, consists of human hepatoma cells from a Japanese male (age 56) and was kindly provided by Drs. Y. Ishikawa and S. Hirohashi (National Cancer Center Research Institute, Tokyo). The Li23 cell line is free of both the hepatitis B virus antigen and HCV (Kato et al., 1995).

2.2. Cell culture

The six HuH-7-derived cell lines: sO cells, harboring the subgenomic replicon RNA of HCV-O (genotype 1b) (Kato et al., 2003a); O cells, harboring a replicative genome-length HCV-O RNA (Ikeda et al., 2005); Oc cured cells, which were created by eliminating HCV RNA from O cells by IFN treatment (Ikeda et al., 2005); OAc cured cells, which were created by eliminating HCV RNA from genome-length HCV-O RNA replicating OA cells (Abe et al., 2007); OR6 cells, harboring the genome-length HCV-O RNA with luciferase as a reporter (Ikeda et al., 2005); RSc cured cells that cell culture-generated HCV-JFH1 (HCVcc) (JFH1 strain of genotype 2a) (Wakita et al., 2005) could infect and efficiently replicate (Ariumi et al., 2007, 2008; Kuroki et al., 2009), or their parental HuH-7 cells were cultured in Dulbecco's modified eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS). The sO, O, and OR6 cells were maintained in the presence of G418 (0.3 mg/ml, Geneticin; Invitrogen). Li23 cells were maintained in modified culture medium for the PH5CH8 human immortalized hepatocyte cell line (Ikeda et al., 1998). The medium for Li23 cells consists of F12 medium and DMEM (1:1 in volume) supplemented with 1% FBS, epidermal growth factor (50 ng/ml), insulin (10 µg/ml), hydrocortisone (0.36 µg/ml), transferrin (5 µg/ml), linoleic acid (5 µg/ml), selenium (20 ng/ml), prolactin (10 ng/ml), gentamycin (10 µg/ml), kanamycin monosulfate (0.2 mg/ml), and fungizone (0.5 µg/ml). Li23-derived cells harboring the HCV replicon or genome-length HCV RNA were cultured in the above medium supplemented with G418 (0.3 mg/ml). The cured Li23-derived cells were maintained in the above medium without G418. The HeLa and HEK293 cells were cultured in DMEM supplemented with 10% FBS.

2.3. Plasmid construction

To introduce the mutations into plasmid pON/3-5B, pON/C-5B, or pORN/C-5B (Ikeda et al., 2005) (GenBank accession no. AB191333; Supplemental Fig. S1), a PCR-based site-directed mutagenesis method was used as previously described (Abe et al., 2007; Mori et al., 2008).

2.4. RNA synthesis

Plasmid DNAs were linearized with XbaI and used for RNA synthesis with the T7 MEGAscript kit (Ambion) as previously described (Kato et al., 2003a). Synthesized RNA was purified by lithium chloride precipitation and dissolved in nuclease-free water.

2.5. RNA transfection and selection of G418-resistant cells

RNA was transfected to Li23 or Li23-derived cells as previously described (Lohmann et al., 1999). Cells were selected in complete medium with G418 (0.3 mg/ml) and sodium bicarbonate solution (0.15%) for 3 weeks as previously described (Kato et al., 2003a). For the staining of G418-resistant colonies, Coomassie brilliant blue

(0.06% in 50% methanol–10% acetic acid) was used as previously described (Ikeda et al., 2005).

2.6. Western blot analysis

The preparation of cell lysates, sodium dodecyl sulfate-polyacrylamide gel electrophoresis and immunoblotting analysis with a PVDV membrane were performed as previously described (Kato et al., 2003a). The antibodies used for the O strain in this study were those against core (CP11; Institute of Immunology), E1 and E2 (a generous gift from Dr. M. Kohara, Tokyo Metropolitan Institute of Medical Science), NS3 (Novocastra Laboratories), NS4A and NS5A (a generous gift from Dr. A. Takamizawa, Research Foundation for Microbial Diseases, Osaka University), and NS5B (a generous gift from Dr. M. Kohara, Tokyo Metropolitan Institute of Medical Science). The antibodies used for the JFH1 strain were those against core (CP11; Institute of Immunology) and NS5B (Murakami et al., 2008). β-Actin antibody (Sigma) was used as the control for the amount of protein loaded per lane. Immunocomplexes were detected by the Renaissance enhanced chemiluminescence assay (PerkinElmer Life Sciences).

2.7. Northern blot analysis

Total RNA from the cultured cells was prepared using an RNeasy extraction kit (Qiagen). Three micrograms of total RNA was used for the analysis. HCV-specific RNA and β-actin mRNA were detected according to a method described previously (Ikeda et al., 2005; Kato et al., 2003a). The synthetic RNA transcribed from pON/3-5B, pON/C-5B, or pORN/C-5B (10⁷ and 10⁸ genome equivalents spiked into cellular total RNA) was used to compare HCV RNA levels.

2.8. Quantification of HCV RNA

Quantitative reverse transcription-polymerase chain reaction (RT-PCR) analysis for HCV RNA was performed using a real-time LightCycler PCR as described previously (Ikeda et al., 2005). We used the following forward and reverse primer sets for the real-time LightCycler PCR: HCV-O, 5'-AGAGCCATAGTGGTCTGCGG-3' (forward), 5'-CTTTCGCGACCCAACACTAC-3' (reverse); and HCV-JFH1, 5'-AGAGCCATAGTGGTCTGCGG-3' (forward), 5'-CTTTCGCAACCCAACGCTAC-3' (reverse). Experiments were done in triplicate.

2.9. Preparation of cured cells

To prepare cured cells, the cells harboring the HCV replicon or genome-length HCV RNA were treated with IFN-γ as described previously (Abe et al., 2007). Briefly, the cells were treated with IFN-γ (1000 IU/ml) in the absence of G418. The treatment was continued for 3 weeks with the addition of IFN-γ at 4-day intervals. The cured cells obtained from O, OA, sOL, OL8, OL11, OL14, ORL8, and ORL11 cells were named Oc, OAc, sOLc, OL8c, OL11c, OL14c, ORL8c, and ORL11c, respectively. RT-PCR confirmed the absence of HCV RNA in these cured cells.

2.10. Immunofluorescence and confocal microscopic analyses

Four days after the cells were seeded on the collagen-coated coverslip, they were fixed with 3% paraformaldehyde in phosphate-buffered saline (PBS) and then permeabilized in 0.1% Triton X-100 in PBS at room temperature. After blocking with 1% bovine serum albumin, the cells were incubated with the primary antibodies and then with the secondary antibody. The primary antibodies used to detect the core and dsRNA were anti-core (CP11; Institute of Immunology) and anti-double-stranded (ds) RNA (K1; English and